Csl vifor and travere therapeutics announce standard eu approval for filspari® in iga nephropathy

European commission converts conditional approval of filspari (sparsentan)  into standard marketing authorization for the treatment of iga nephropathy (igan) decision follows positive recommendation from committee for medicinal products for human use (chmp) from february 2025 eu approval is based on the complete data set from the phase-iii protect study st. gallen, switzerland and san diego , april 29, 2025 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) are pleased to announce that the european commission has approved the conversion of the conditional marketing approval (cma) into a standard marketing authorization (ma) for filspari for the treatment of adults with primary iga nephropathy with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
TVTX Ratings Summary
TVTX Quant Ranking